HomeBUSINESS
BUSINESS

Zytiga Gets Priority Review Status for Earlier Use in Prostate Cancer
(Oct.11.2017)

Janssen Pharmaceutical said on October 10 that the Japanese health ministry granted its prostate cancer drug Zytiga (abiraterone) a priority review status for an additional indication of hormone therapy-naïve patients with metastatic prostate cancer ...
(LOG IN FOR FULL STORY)

News Calendar